Browse Reports

G-III Apparel Group, Ltd. is a publicly traded company listed on the Nasdaq Stock Market under the ticker GIII. The company operates in the fashion industry, competing in intensely competitive markets. It maintains a strong liquidity position with a current ratio of 2.69 and cash ratio of 0.75 as of January 31, 2026. The company reported net income of $67.4 million and basic earnings per share of $1.58 for the fiscal year ended January 31, 2026. Recent corporate actions include the declaration of a quarterly cash dividend and the granting of long-term restricted stock unit awards to key senior leaders as part of succession planning and retention strategies. The company’s stock experienced a notable decline following Q4 earnings results that showed a year-over-year sales dip and a loss in the quarter, with market conditions also influenced by broader economic factors such as rising crude oil prices and geopolitical tensions.

Grayscale Sui Staking ETF is an investment trust that holds the SUI digital asset and engages in staking activities to generate returns for shareholders. The Trust operates within the digital asset ecosystem, which is characterized by high volatility, regulatory uncertainty, and evolving technology. The Sponsor oversees the Trust's operations, including cybersecurity and third-party risk management. The Trust's Shares trade on NYSE Arca and may trade at prices differing from the Trust's NAV due to market and liquidity factors. The Trust is subject to various risks including market volatility, regulatory changes, operational dependencies on third parties, and staking-related risks.

Blaize Holdings, Inc. is a Delaware corporation headquartered in El Dorado Hills, California, that develops AI-enabled computing solutions. Its product portfolio includes the GSP AI computing accelerator, compute cards, and a software suite including Blaize AI Studio. The company integrates third-party hardware, primarily servers, to provide comprehensive AI computing solutions for edge and data center deployments. Blaize also offers strategic consulting services. Manufacturing is fully outsourced to partners including Samsung Foundry and Plexus. Revenue is concentrated among a few customers, with a significant portion derived from third-party hardware sales. The company has not yet achieved profitability and has a history of operating losses. It holds a portfolio of patents related to AI and parallel processing. Blaize faces risks from customer concentration, supply chain dependencies, regulatory changes, and macroeconomic factors.

MV Oil Trust was formed in 2006 to hold a net profits interest in oil and natural gas properties owned by MV Partners, LLC. The Trust's interest entitles it to 80% of net proceeds from production of the underlying properties, which are located in Kansas and Colorado. The properties produce primarily oil from approximately 830 wells with long reserve lives. Operations are conducted by contract operators affiliated with MV Energy, LLC. The Trust itself has no employees and is managed by a trustee. Trust Units trade on the NYSE under the ticker MVO, with distributions made quarterly from net proceeds after expenses and reserves. The Trust is scheduled to wind up and terminate after June 30, 2026, at which point no further distributions will be made.

VOC Energy Trust was formed in 2010 to acquire and hold an 80% net profits interest in oil and natural gas properties owned by VOC Brazos Energy Partners, L.P. The Trust's interest entitles it to receive 80% of net proceeds from production and sales after deducting costs such as royalties, taxes, operating expenses, and development costs. The Trust does not operate the properties; operations are conducted by VOC Operators including Vess Oil Corporation. The Trust has no employees and is managed by a Trustee. The net profits interest is passive and will terminate on the later of December 31, 2030, or when specified production thresholds are met. The Trust Units trade on the New York Stock Exchange under the ticker VOC.

Strategic Storage Trust VI, Inc. is a Maryland-based real estate investment trust focused on investing in self storage facilities in the United States and Canada. Formed in 2020 and commencing operations in 2021, the company operates through an affiliated advisor and property manager, both subsidiaries of its sponsor, SmartStop REIT Advisors, LLC, itself an indirect subsidiary of SmartStop Self Storage REIT, Inc. The company owns a portfolio of 24 operating self storage properties across seven U.S. states and three Canadian provinces, along with two development properties and a 50% interest in five unconsolidated real estate ventures. Its properties offer month-to-month rental units to residential and commercial customers, featuring climate control, vehicle access, and security. The company leverages a technology-driven platform for marketing, pricing, and leasing, including digital and contactless rental options. It has multiple classes of common stock and preferred equity securities, with offerings conducted through private placements, public offerings, and distribution reinvestment plans. The company reported revenues of approximately $30.7 million and a net loss of $24.0 million for the fiscal year ended 2025-12-31, with cash and cash equivalents of $8.8 million. The company’s investment strategy emphasizes geographic diversification, property expansion, and professional management to improve profitability and cash flow sustainability.

Biomea Fusion, Inc. is a clinical-stage biotechnology company developing novel small molecule therapies primarily targeting metabolic disorders such as type 1 and type 2 diabetes and obesity, alongside oncology assets. Founded in 2017, the company has not yet commercialized any products or generated revenue. Its lead product candidate, icovamenib, is undergoing Phase II clinical trials for diabetes indications. The company also has BMF-650 in Phase I trials and BMF-500, an oncology asset, in early clinical development. Biomea Fusion utilizes its proprietary FUSION™ System platform for drug discovery. The company finances operations through equity offerings and has incurred significant net losses, reflecting ongoing research and development expenses. As of December 31, 2025, it held approximately $55.8 million in cash and equivalents, with strong liquidity ratios. The company has implemented a strategic realignment to focus on core diabetes programs and optimize its cash runway. It faces typical early-stage biotech risks including clinical, regulatory, financial, and operational challenges.

ECA Marcellus Trust I operates as a statutory trust owning royalty interests in natural gas properties primarily in the Marcellus Shale formation in Greene County, Pennsylvania. The Trust's assets include royalty interests in 14 producing wells and 40 development wells completed as of late 2025. The Trust does not engage in operational activities but receives cash flows from natural gas production after deducting post-production costs and administrative expenses. Greylock Production serves as the operator, and Greylock Midstream handles marketing and gathering. The Trust has a defined termination date in 2030, after which it will liquidate its assets. The Trust units represent passive interests with no control over operations or management.

LENZ Therapeutics, Inc. is a pharmaceutical company specializing in the development and commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia in adults. The product received FDA approval in July 2025 and was launched commercially in the United States in August 2025. The company has a limited operating history and has incurred significant net losses since inception, funding operations primarily through equity financing. LENZ's business model centers on the successful commercialization of VIZZ, with no other product candidates currently in development. The company has established licensing agreements with partners for commercialization in international markets such as South Korea and Greater China. Financially, as of December 31, 2025, LENZ held $25.2 million in cash and equivalents and maintained a strong liquidity position with a current ratio of 14.23. The company faces risks related to market acceptance of VIZZ, competition from other presbyopia treatments, reliance on third-party manufacturers and license partners, and the challenges inherent in scaling sales and marketing operations.

VirnetX Holding Corporation develops patented cybersecurity software and technology solutions designed to ensure secure, resilient communications across networks and devices. Its core products include VirnetX One™, a security-as-a-service platform based on Zero Trust Network Access principles, VirnetX Matrix™, which provides encrypted, identity-based access controls for enterprise applications, and VirnetX War Room™, a secure collaboration platform for sensitive communications. The company serves U.S. Department of Defense, federal government, and commercial customers across various sectors such as critical infrastructure, healthcare, financial services, and legal. VirnetX also engages in strategic partnerships, research collaborations, and international sales compliant with U.S. export regulations. The company is advancing its technology roadmap with developments in federated mesh networks, Model-Based Systems Engineering, and cyber threat intelligence services aligned with defense digital engineering strategies. As of December 31, 2025, VirnetX had 21 employees primarily focused on research and development.

Comstock Inc. is a company engaged in metals and recycling operations, including the development and expansion of end-of-life solar facilities in multiple U.S. states. The company also holds and sells mining-related royalties and is actively expanding its metals recycling network. It completed a significant public offering in early 2026 to support capital expenditures and growth initiatives. Financial disclosures indicate modest revenue with a substantial net loss as of the fiscal year ending December 31, 2025.

Fractyl Health, Inc. develops and plans to commercialize medical devices and gene therapy candidates targeting metabolic diseases such as obesity and type 2 diabetes. Its primary product candidate, Revita, is a device-based duodenal mucosal resurfacing procedure designed to improve metabolic health. The company is navigating regulatory pathways in the U.S., EU, and UK, including transitioning its device certification from the EU Medical Device Directive to the Medical Device Regulation and complying with UKCA marking requirements. Manufacturing depends on third-party sole-source suppliers without long-term agreements, posing supply chain risks. Clinical development includes ongoing studies in the U.S. and EU, with potential future studies outside the U.S. Fractyl Health has not generated revenue and reported significant net losses, reflecting its pre-commercial stage. The company’s sales cycle is expected to be lengthy and variable, involving multiple healthcare stakeholders and payors. Recent management changes and clinical data releases have been reported, alongside notable share price volatility.

BioCardia, Inc. develops cellular and cell-derived therapeutics targeting cardiovascular and pulmonary diseases with significant unmet needs. Its primary platform, CardiAMP®, is an autologous mononuclear cell therapy aimed at treating ischemic heart failure with reduced ejection fraction and refractory angina due to chronic myocardial ischemia. The company also develops an allogeneic mesenchymal stem cell therapy for ischemic inflammatory heart failure and has an investigational program for acute respiratory distress syndrome. BioCardia's Helix™ transendocardial delivery system enables minimally invasive catheter-based delivery of therapeutics to the heart and is used both internally and in partnerships. The company has conducted multiple clinical trials, including pivotal and Phase III studies, with results showing safety and signals of efficacy in patient subgroups. Revenues are modest and derived mainly from partnering agreements and sales of FDA-cleared delivery devices. The company has incurred net losses since inception and relies on equity and convertible debt financing alongside grants to fund operations. [S1]

Neurogene Inc. focuses on developing gene therapies for severe neurological diseases with high unmet medical need. The company’s proprietary EXACT technology enables precise control of transgene expression via microRNA-based genetic circuits, aiming to overcome limitations of conventional gene therapy such as variable expression and toxicity. Founded in 2018, Neurogene has concentrated on research, clinical development, and establishing in-house manufacturing capabilities. Its lead candidate, NGN-401, targets Rett syndrome, a rare neurodevelopmental disorder caused by MECP2 gene mutations with a narrow therapeutic window for gene therapy. NGN-401 is delivered via intracerebroventricular infusion and is in Phase 3 clinical trials. The company has reported positive interim clinical data and operates a fully operational cGMP manufacturing facility in Houston, Texas. Neurogene has incurred significant losses since inception, with no approved products or commercial revenue, and plans to continue funding operations through capital raises and collaborations. The company collaborates with the University of Edinburgh and employs a team with expertise in gene therapy development and manufacturing.

GameStop Corp. is a specialty retailer established in 1996, offering games, collectibles, and entertainment products through thousands of stores and ecommerce platforms. The company operates in three geographic segments: United States, Australia, and Europe, having divested its Canadian operations in fiscal 2025. GameStop’s business model is evolving beyond traditional retail to include disciplined capital allocation aimed at value creation through acquisitions and control transactions. The company has focused on expanding its collectibles business, which grew to represent 29% of total sales in fiscal 2025, supported by initiatives such as graded trading card submission services and the launch of the Power Packs digital trading card platform in partnership with PSA. Store fleet optimization led to the closure of 727 U.S. stores in fiscal 2025, with no significant closures planned for fiscal 2026. The company continues to streamline international operations, including divestitures in Canada and New Zealand. Fiscal 2025 net sales declined 5.1% to $3.63 billion, driven by decreases in software and hardware sales but partially offset by a 47.7% increase in collectibles sales. Gross profit and margin improved due to a favorable sales mix. SG&A expenses decreased significantly due to cost optimization efforts. GameStop maintains a strong liquidity position with $6.3 billion in cash and $2.7 billion in marketable securities as of January 31, 2026. The company’s investment policy includes cash equivalents, fixed income, equity securities, and cryptocurrencies such as Bitcoin, which it holds as a treasury reserve asset. The company recorded losses related to its Bitcoin holdings due to market price declines and a covered call strategy. Management and the Audit Committee oversee cybersecurity risk and information security programs.

Commercial Bancgroup, Inc. is a bank holding company headquartered in Harrogate, Tennessee, operating primarily through its wholly owned subsidiary, Commercial Bank. The bank is a full-service community banking institution offering traditional consumer and commercial banking products and services to businesses and individuals in select markets across Tennessee, Kentucky, and North Carolina. As of December 31, 2025, the company operated 34 banking offices and one loan production office, with total consolidated assets of $2.3 billion, loans net of allowance of $1.9 billion, deposits of $1.8 billion, and shareholders' equity of $285.3 million. The company completed its initial public offering in October 2025, raising net proceeds of approximately $29.9 million. The bank's business strategy emphasizes growth through both acquisitions and organic expansion, focusing on superior customer service, market share growth in deposits and loans, and leveraging technology to enhance customer experience and operational productivity. The company targets small and medium-sized businesses, corporate customers, commercial real estate owners, and consumers, with a strong focus on relationship banking and core deposits to fund loan growth. The bank operates in a competitive environment with local, regional, and national financial institutions and non-bank financial service providers. Risk management is integral to the company's operations, with oversight by the board and committees on various risk exposures including credit, liquidity, interest rate, operational, compliance, cybersecurity, and reputational risks. The company maintains well-capitalized regulatory capital ratios and has made significant investments in technology platforms and employee development.

Fifth District Bancorp, Inc. was incorporated in February 2024 and became the holding company for Fifth District Savings Bank following its conversion from a mutual to stock form of organization in July 2024. The bank operates primarily in the New Orleans-Metairie Metropolitan Statistical Area through a main office and six branches. Its loan portfolio is predominantly fixed-rate one- to four-family residential mortgage loans, which accounted for 86.3% of total loans at year-end 2025. The company also originates and purchases commercial real estate, commercial and industrial loans, and other loan types. It retains most loans in its portfolio and emphasizes conservative underwriting standards, avoiding adjustable rate, interest-only, negative amortization, and subprime loans. Deposits are the primary funding source, with a focus on growing low-cost core deposits. The company offers a range of deposit accounts and electronic banking services. It is regulated by the Federal Reserve Board, OCC, and FDIC. At December 31, 2025, total assets were $534.4 million, loans $376.4 million, deposits $393.2 million, and stockholders’ equity $129.8 million. The company reported net income of $4.1 million and basic and diluted EPS of $0.80 for 2025. It faces strong competition in its market area from various financial institutions. The company recently authorized a buyback of up to 10% of outstanding shares [N1][S1].

Cayson Acquisition Corp operates as a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model centers on identifying and completing a merger or similar business combination with one or more target companies, primarily in Asia but without industry or geographic restrictions. The company raised gross proceeds of $60 million through its IPO and an additional $2.3 million via a private placement, with funds held in a trust account invested in U.S. government securities. It has not generated operating revenues and incurs costs related to formation, administration, and identifying a target. The company entered into a merger agreement with Mango Financial Limited in July 2025 and extended the deadline to consummate a business combination to March 2027. The company’s management includes CEO Yawei Cao and affiliated sponsors. The company’s financial position includes significant trust account assets but limited liquidity outside the trust account, with a current ratio of 0.12 as of December 31, 2025.

Curis Inc is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of small molecule compounds targeting immuno-oncology and precision oncology. Its lead candidate, emavusertib (CA-4948), is an orally available inhibitor of IRAK4 and FLT3, developed under an exclusive collaboration with Aurigene Discovery Technologies Limited. The collaboration grants Curis options for exclusive licenses to develop and commercialize products globally, excluding India and Russia, with milestone and royalty payment obligations. The company previously derived revenues from royalties on Erivedge, a Hedgehog pathway antagonist licensed to Genentech, but sold its royalty interest in late 2025, ceasing related revenues. Curis finances operations through equity offerings, license fees, research funding, and royalty monetization. The company operates in a single segment focused on oncology drug development, with all assets located in the United States.

Brookfield Oaktree Holdings, LLC operates as a limited liability holding company primarily engaged in holding limited partner interests and capital commitments in Oaktree Opportunities Funds XI and XII, which are parallel investment vehicles or feeder funds. The company’s sole Class A unitholder contributes cash to fund these investments, and distributions from these investments benefit the Class A unitholder. The company accounts for its approximately 74% interest in Oaktree Capital I under the equity method following a 2024 restructuring. Revenue primarily consists of investment income from these funds and indirect ownership in Brookfield REIT. The company’s preferred units receive distributions generally serviced by distributions from Oaktree Capital I, but there is no guarantee of sufficient cash flow. The company’s operating agreement limits remedies available to preferred unitholders and modifies fiduciary duties of officers and directors. The company is not considered an investment company under the Investment Company Act, focusing on asset management services rather than investing or trading securities. The business depends on key personnel and services provided by Oaktree Capital Management and Brookfield, with risks related to regulatory compliance, investment leverage, liquidity, valuation, and tax complexities.

SUPA Consolidated Inc. is a Nevada-based company that has undergone multiple strategic transformations since its incorporation in 2014. Initially engaged in property tax lien services, the company shifted focus in 2020 to developing ridesharing and autonomous vehicle technologies, supported by patented software. In December 2024, SUPA sold its intellectual property and related assets to Boumarang Inc., receiving shares valued at $5 million, and discontinued its transportation technology operations. Subsequently, the company pivoted to the food technology sector, acquiring SUPA Food Services LLC in mid-2025, which operates commercial ice and water vending machines. The company is currently in a development phase, with no operating revenues and a business model centered on identifying, developing, and acquiring food technology assets. Operations are conducted through directors, officers, and third-party consultants, with no full-time employees as of the end of 2025.

ITHAX Acquisition Corp III is a Cayman Islands-based special purpose acquisition company (SPAC) that completed its initial public offering in December 2025, raising $230 million through the issuance of units consisting of Class A ordinary shares and redeemable warrants. The proceeds from the IPO and related private placements are held in a trust account. The company reported no revenue and a net loss of $56,044 for the fiscal year ended December 31, 2025. It maintains strong liquidity with a current ratio of 9.84 as of the same date. The company is classified as an emerging growth company and has entered into multiple agreements related to its IPO and warrant issuance. Detailed information on business operations, products, or customers has not been disclosed in the filings to date.

Millicom International Cellular S.A. (Millicom) is a leading telecommunications provider focused on emerging markets in Latin America. Operating under the Tigo brand, Millicom offers a broad range of mobile and fixed services, including mobile voice, data, SMS, mobile financial services (Tigo Money), broadband, pay-TV, fixed voice, and business solutions such as cloud and managed services. The company serves approximately 49.3 million mobile subscribers and 4.6 million fixed service customer relationships across Bolivia, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras (joint venture), Nicaragua, Panama, Paraguay, and Uruguay. Millicom’s infrastructure includes thousands of towers, extensive fiber networks, and data centers. The company’s strategy centers on expanding network capacity and distribution to increase penetration in under-served markets. Millicom reported $5.819 billion in revenue and $1.316 billion in net profit for 2025, with a strong liquidity position and ongoing capital investments to support network growth. The company’s organizational structure was streamlined recently to enhance operational focus and profitability.

Sanara MedTech Inc. develops and commercializes medical technologies aimed at improving clinical outcomes and reducing healthcare costs in the surgical market. The company’s product portfolio focuses on soft tissue repair and bone fusion products used in operating rooms and sterile environments. Key products include CellerateRX Surgical Powder, a hydrolyzed collagen aiding surgical wound healing, and BIASURGE Advanced Surgical Solution, a sterile wound irrigation product with antimicrobial properties. Bone fusion offerings include BiFORM Bioactive Moldable Matrix and ALLOCYTE Plus Advanced Viable Bone Matrix. The company discontinued its Tissue Health Plus (THP) value-based wound care services program in 2025 due to persistent losses and lack of investor interest, refocusing solely on surgical products. Sanara MedTech operates a single reportable segment and relies on contract manufacturers for production. It has a commercial network covering over 4,000 hospitals and is expanding its geographic footprint in the U.S. The company is advancing a pipeline of next-generation products and has partnered to commercialize new technologies such as OsStic BioAdhesive. Recent clinical and preclinical studies support the efficacy and safety of its products. Financially, the company reported approximately $103 million in revenue for 2025 and a net loss of $37.6 million, including discontinued operations related to THP. Sanara MedTech holds a strong leadership team with experience in the surgical market.

Titan America SA, incorporated in Belgium in 2024 and majority owned by Titan SA, is a leading vertically integrated manufacturer and supplier of heavy building materials in the US Southeast and Mid-Atlantic regions. The company operates two reportable segments: Florida and Mid-Atlantic, each encompassing cement production, aggregates mining, ready-mix concrete, concrete block manufacturing, fly ash processing, and related logistics including marine import terminals and rail infrastructure. The Florida segment includes the Pennsuco cement plant, the largest in Florida by capacity, and the Port Tampa Bay Terminal, a key import and storage facility. The Mid-Atlantic segment includes the Roanoke cement plant, the only cement plant in Virginia, and terminals in Norfolk and Essex serving the Mid-Atlantic and Metro New York markets. Titan America emphasizes sustainability through production of lower-carbon cement, use of alternative fuels, and recycling initiatives. The company completed its IPO in February 2025 and reported net income of $185.4 million for the fiscal year ended December 31, 2025. It maintains strong liquidity and continues to invest in growth, productivity, and maintenance capital expenditures.

Chicago Rivet & Machine Co. manufactures and sells rivets, cold-formed fasteners, screw machine products, and automatic rivet setting machines and related parts. The company operates two main segments: Fastener and Assembly Equipment. The Fastener segment serves primarily the automotive industry but has expanded into non-automotive sectors such as construction and electronics. Revenue recognition varies by segment, with assembly equipment revenue recognized based on progress toward completion. The company has experienced fluctuating sales and profitability, with recent quarters showing both operating income and losses. The company maintains a revolving credit facility and has disclosed liquidity challenges and going concern risks in recent SEC filings. The company pays dividends but reduced its dividend rate in late 2024. The CEO and CFO certify financial reports, and the company maintains a code of ethics and governance committees.

SOUTHERN CALIFORNIA EDISON Co (SCE) is an electric utility company and a wholly-owned subsidiary of Edison International. It operates through its subsidiary SCE Recovery Funding LLC, which manages asset-backed securities and recovery property transactions. The company’s SEC filings for the fiscal year ended December 31, 2025, omit key sections such as business description, risk factors, and management discussion pursuant to SEC General Instruction J, limiting public visibility into its current operations and strategy. The most recent detailed financial data publicly available dates back to mid-2014, reflecting a revenue base of approximately $3 billion and net income of $536 million for that period. SCE Recovery Funding LLC has executed multiple property purchase and sale agreements and servicing agreements with SCE, indicating ongoing structured financing activities.

Circle Energy, Inc. is a Nevada-based exploration-stage oil and natural gas company formed in December 2021. The company focuses on acquiring and developing oil and natural gas properties in the Permian Basin region of Texas. It currently owns a 75% working interest and 55.5% net revenue interest in an 80-acre leasehold in Andrews County, Texas. The company has not drilled any wells or established proved reserves and has no producing wells. Its primary activities include evaluating leasehold interests, pursuing additional acreage acquisitions, and seeking financing to drill and develop properties. Circle Energy operates under a farmout agreement requiring drilling of two wells by May 16, 2028, or rights to undrilled tracts revert to the lessor. The company has also entered a joint venture to develop an area of mutual interest of approximately 880 acres adjoining its current lease. The company is in the startup phase, with no revenues or customers to date, and incurs general and administrative expenses related to corporate and compliance activities. It uses the full cost method for accounting oil and natural gas properties and maintains a strong liquidity position with cash and current assets significantly exceeding current liabilities as of December 31, 2025.

VenHub Global, Inc. develops and commercializes autonomous retail stores branded as VenHub Smart Stores. These stores operate 24/7 without employees, using robotics and AI for product selection, bagging, delivery, and inventory management. The company’s technology integrates advanced sensors, AI-driven operational functions, and a mobile app for customer interaction. VenHub’s business model includes selling smart store units and providing software as a service through its subsidiaries. The company holds a significant intellectual property portfolio with pending patents covering its robotics and AI innovations. VenHub is in the early stages of commercialization, with limited revenue and deployment experience, and operates two company-owned stores in strategic locations. The company faces challenges typical of startups, including capital needs, competition, and supply chain risks.

CreditRiskMonitor.com, Inc. operates as a Software-as-a-Service (SaaS) provider specializing in business-to-business (B2B) corporate financial risk analysis. Its primary products, CreditRiskMonitor® and SupplyChainMonitor™, offer subscribers access to comprehensive commercial credit reports, bankruptcy risk analytics, financial data, and curated news on millions of public and private companies globally. The company’s flagship CreditRiskMonitor® platform is widely used by corporate credit professionals to assess trade credit risk and manage counterparty financial risk, featuring proprietary bankruptcy prediction scores (FRISK® and PAYCE®), detailed financial statement analyses, and proactive alerts. SupplyChainMonitor™ targets procurement and supply chain professionals, providing tools for supplier risk assessment, location mapping with real-time event overlays, and macro-level geopolitical risk data. The company’s SaaS products are sold primarily through upfront annual payments to a diverse subscriber base, including a significant portion of Fortune 1000 companies. CreditRiskMonitor.com emphasizes automation and proprietary algorithms to deliver high-quality, cost-effective financial risk information, supported by a Trade Contributor Program aggregating approximately $3 trillion in trade credit transaction data annually. The company faces competition from larger firms such as Dun & Bradstreet but maintains a niche with specialized bankruptcy analytics and supply chain risk tools.

Perma-Fix Environmental Services, Inc. is a Delaware corporation headquartered in Atlanta, Georgia, providing nuclear and mixed waste management services. Its Treatment Segment offers licensed treatment and disposal of radioactive, mixed, hazardous, and non-hazardous waste through four facilities, while its Services Segment provides technical, radiological, health physics, occupational safety, and nuclear decontamination and decommissioning services. The company serves government entities including the DOE and DOW, commercial clients, and international customers in Canada, Mexico, Europe, and the UK. It has expanded its international revenue significantly and is developing innovative PFAS destruction technology. The company’s operations are subject to extensive environmental regulations and seasonal factors affecting revenue.

Leatt Corp is a Nevada-incorporated company specializing in personal protective equipment (PPE) for motor sports and leisure activities such as motorcycling, bicycling, snowmobiling, and ATV riding. The company holds exclusive global rights to the patented Leatt-Brace® neck protection system, designed to prevent cervical spine injuries. Its product portfolio includes neck braces, helmets, body protection gear, goggles, sunglasses, and technical apparel marketed under the Leatt® brand. Manufacturing is outsourced primarily to third-party manufacturers in China, with expanding capacity in Thailand, Cambodia, and Bangladesh. The company maintains strict quality control through on-site inspections. Leatt sells its products worldwide through approximately 61 distributors and 6 e-commerce partners, with direct distribution in the U.S. and South Africa. The company invests in research and development at its Cape Town headquarters and holds multiple international safety certifications for its products. Revenue is diversified across international and domestic markets, with no single customer accounting for more than 10% of consolidated revenues. Leatt pays licensing fees to Xceed Holdings for the Leatt-Brace® technology. The company has demonstrated revenue growth and profitability in recent periods.

FTC Solar, Inc., founded in 2017 and headquartered in Austin, Texas, designs and manufactures solar tracker systems that optimize the orientation of solar panels to increase energy production. Its product portfolio includes the Pioneer 1P and Voyager 2P solar tracker systems, mounting solutions for U.S.-manufactured thin-film modules, and proprietary software platforms SUNPATH and SUNOPS for solar tracking optimization and real-time operations management. The company serves primarily EPCs, developers, and owners in utility-scale and distributed solar projects globally, with subsidiaries in Australia, China, India, South Africa, and Spain. FTC Solar acquired Alpha Steel in 2025 to enable domestic manufacturing of key components. The company’s revenue is derived from product sales and services including engineering consulting and software licenses. It operates under a Credit Agreement providing secured financing, but faces risks related to financial covenants, customer concentration, supply chain, tariffs, and competitive pressures.

Ocean Thermal Energy Corp specializes in developing renewable energy systems using proprietary technology for Ocean Thermal Energy Conversion (OTEC), Seawater Air Conditioning (SWAC), and Lake Source Cooling (LSC). These technologies harness temperature differences between warm surface water and cold deep seawater to generate electricity, provide air conditioning, and produce desalinated water. The company targets tropical and subtropical regions globally, including projects with the U.S. Department of Defense and other international partners. To date, no commercial projects have been completed, but development efforts continue. The company plans to finance projects through long-term power purchase agreements and energy service agreements, seeking development fees and equity stakes. Financially, the company reported revenues but incurred significant net losses and faces liquidity challenges as of the latest fiscal year.

Core & Main, Inc. operates as a holding company primarily owning Core & Main Holdings, LP. It is a leading specialty distributor dedicated to advancing reliable infrastructure with local service nationwide. The company focuses on water, wastewater, storm drainage, and fire protection products and related services, serving municipalities, private water companies, and professional contractors across municipal, non-residential, and residential end markets. Core & Main offers over 225,000 products that meet regulatory and engineering standards. As of February 1, 2026, it operated more than 370 branch locations in the U.S. and Canada, connecting over 5,000 suppliers with more than 60,000 customers. The company’s sales are balanced across product categories and end markets, with approximately 44% of net sales from municipal markets, 38% from non-residential, and 18% from residential markets. The business model relies on extensive local expertise combined with nationwide reach, technical knowledge, and project delivery capabilities. Core & Main also performs light fabrication services for certain product categories, adding operational complexity. The company’s financial position as of fiscal 2025 shows solid liquidity and profitability, with net income of $441 million and a current ratio of 2.63. It faces risks related to market cyclicality, municipal spending, competitive bidding, product cost volatility, supply chain disruptions, indebtedness, and credit risk from customers. Recent news reports indicate positive earnings results and sales growth in fiscal 2026.

COMPASS Pathways plc is a clinical-stage biotechnology company developing psilocybin-based therapeutics, with a lead candidate COMP360 targeting treatment-resistant depression (TRD). The company has not yet generated revenue and has incurred substantial operating losses primarily due to research and development and administrative expenses. It is conducting Phase 3 clinical trials for COMP360 and plans to initiate late-stage development for PTSD. The company is preparing for regulatory submissions and potential commercialization, including training healthcare professionals and establishing sales and marketing infrastructure. Funding is currently supported by cash reserves, outstanding warrants, and a loan agreement with financial covenants. The company faces regulatory, manufacturing, financial, and legal risks inherent to clinical-stage biopharmaceutical development.